Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EVGN.TA
- Price
- 454.80
- Stock movement down
- -6.80 (-1.47%)
- Company name
- Evogene
- Exchange
- (TA ,
- Currency
- ILA )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.09B
- Ent value
- 3.10B
- Price/Sales
- 326.95
- Price/Book
- 154.93
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -10.15%
- 1 year return
- -83.75%
- 3 year return
- -52.15%
- 5 year return
- -38.45%
- 10 year return
- -35.44%
Last updated: 2025-04-04
DIVIDENDS
EVGN.TA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 326.95 |
| Price to Book | 154.93 |
| EV to Sales | 328.17 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 6.79M |
| EPS (TTM) | -3.90 |
| FCF per share (TTM) | -3.98 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 9.45M |
| Gross profit (TTM) | 7.69M |
| Operating income (TTM) | -22.00M |
| Net income (TTM) | -19.87M |
| EPS (TTM) | -3.90 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 81.42% |
| Operating margin (TTM) | -232.82% |
| Profit margin (TTM) | -210.26% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 9.48M |
| Net receivables | 376.00K |
| Total current assets | 25.77M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 2.38M |
| Total assets | 40.97M |
| Accounts payable | 957.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 5.89M |
| Total liabilities | 21.03M |
| Shareholder's equity | 19.94M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -19.81M |
| Capital expenditures (TTM) | 474.00K |
| Free cash flow (TTM) | -20.28M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -99.63% |
| Return on Assets | -48.49% |
| Return on Invested Capital | -65.50% |
| Cash Return on Invested Capital | -66.86% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 465.50 |
| Daily high | 465.50 |
| Daily low | 437.00 |
| Daily Volume | 16K |
| All-time high | 128920.00 |
| 1y analyst estimate | 5.50 |
| Beta | 1.08 |
| EPS (TTM) | -3.90 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 21 May 2025 |
Downside potential
Loading...
Downside potential data
| EVGN.TA | S&P500 | |
| Current price drop from All-time high | -99.65% | -12.44% |
| Highest price drop | -99.65% | -56.47% |
| Date of highest drop | 18 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -63.39% | -11.07% |
| Avg time to new high | 62 days | 12 days |
| Max time to new high | 2803 days | 1805 days |
COMPANY DETAILS
Marketcap
3.09B
Marketcap category
Mid-cap
Description
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Employees
142
Website
Investor relations
-
SEC filings
CEO
Country
Israel
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Evogene Ltd (EVGN) reports significant revenue increase and strategic partnerships, despite ongoing challenges in R&D and operating expenses.
March 7, 2025
REHOVOT, Israel (AP) — Evogene Ltd. (EVGN) on Thursday reported profit of $427,000 in its fourth quarter. On a per-share basis, the Rehovot, Israel-based company said it had profit of 6 cents. The agr...
March 6, 2025
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products, today announced its financial results for the ...
March 6, 2025
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced the appointment of Mr. N...
March 6, 2025
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its fi...
February 20, 2025
AgPlenus Ltd., a global leader in designing and developing novel sustainable crop protection products and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced the breakthrough dis...
February 13, 2025
Evogene Ltd (EVGN) Q3 2024 Earnings Call Highlights: Navigating Challenges and Seizing Opportunities
Despite a dip in quarterly revenue, Evogene Ltd (EVGN) advances with strategic collaborations and promising future prospects.
November 22, 2024
REHOVOT, Israel (AP) — Evogene Ltd. (EVGN) on Thursday reported a loss of $7.6 million in its third quarter. The Rehovot, Israel-based company said it had a loss of $1.31 per share. The agricultural c...
November 21, 2024
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene" or the "Company"), a leading computational biology company aiming to revolutionize the development of life-science-based products, today announced i...
November 21, 2024
Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced significant progress in the development of its LAV321 bio-fungicide, target...
November 19, 2024
Next page